Athersys, Inc. - ATHX STOCK NEWS

Athersys, Inc. (NASDAQ: ATHX) will be participating in three upcoming conferences in May. Chris Temple will be attending the Pharma Manufacturing World Summit and Allogeneic Cell Therapies Summit, while Dr. Sarah Busch will be attending the American Thoracic Society’s Respiratory Innovation Summit. The conferences will focus on topics such as cell and gene therapies, supply chain management, and new treatments for respiratory diseases.

Athersys (NASDAQ: ATHX), a regenerative medicine company, will participate in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023, in Clearwater, FL. Dr. Sarah Busch, VP of Regenerative Medicine, will present a talk titled “MultiStem^® Cellular Therapy for Neurological Indications” on April 28th at 9:00 a.m. ET and partake in a panel discussion on the career development of female neuroscientists later that day at 4:50 p.m. ET. Additionally, she will co-chair a panel on translating treatments for neural injury on April 29th at 2:30 p.m. ET. Athersys aims to advance knowledge in the field and explore collaborative opportunities at this prestigious event.

Athersys, Inc. (NASDAQ: ATHX) has successfully completed an offering of 3,685,000 shares of common stock at a price of $1.00 per share, generating gross proceeds of approximately $3.7 million. This offering included warrants for purchasing an equal number of shares at an exercise price of $0.96. The offering was conducted under an effective shelf registration statement with the SEC. Athersys plans to utilize the net proceeds for general corporate purposes. The warrants are set to be exercisable starting six months post-issuance and will expire seven years later. A.G.P./Alliance Global Partners acted as the sole placement agent.

Athersys, Inc. (Nasdaq: ATHX) has announced a registered direct offering of 3,685,000 shares of its common stock at a price of $1.00 per share. The offering includes warrants for investors to purchase an equal number of shares at an exercise price of $0.96. The expected gross proceeds are approximately $3.7 million, which will be used for general corporate purposes. The offering's closing is anticipated on or about April 19, 2023, pending customary conditions. The shares are offered under an effective shelf registration statement with the SEC, while the warrants are part of a private placement and are not registered under the Securities Act.

Alliance Global Partners is acting as the sole placement agent for the offering.

Athersys, Inc. (NASDAQ: ATHX), a leader in cell therapy and regenerative medicine, has announced a business update conference call scheduled for April 20, 2023, at 11:00 a.m. Eastern Time. The call will feature key executives including CEO Dan Camardo, COO Maia Hansen, Interim CFO Kasey Rosado, and EVP Willie Mays. They will discuss the company's recent clinical advancements and upcoming milestones related to the pivotal Phase 3 ischemic stroke trial, MASTERS-2.

The company invites participants to submit questions in advance via email. A replay of the call will be available on the Athersys website for those unable to attend the live session. Athersys is developing its innovative MultiStem^® (invimestrocel) therapy, which is designed to address critical care needs through tissue repair and healing.

Athersys, Inc. (NASDAQ: ATHX) announced its financial results for Q4 and the full year 2022, highlighting significant restructuring efforts. The company reduced operating expenses below $3 million monthly, a drop from $7 million last year, and decreased its headcount by 70% to 20 employees. Revenues for Q4 totaled $0.1 million, down from $0.7 million, while full-year revenues were $5.3 million, a 3.6% decline compared to 2021. The net loss narrowed to $13.0 million or $0.83 per share in Q4, with a total annual net loss of $72.5 million. Athersys is focusing on the Phase 3 MASTERS-2 trial in ischemic stroke and expects lower R&D expenses in 2023.